Korean J Transplant.  2020 Dec;34(Supple 1):S93. 10.4285/ATW2020.PO-1238.

Differential impact of allograft rejection on kidney transplant patients with BK virus infection

• Min JW
• Park JB
• Park JH
• Park JW
• Yang J
• Ahn C
• Yang CW
• Chung BH

• KMID: 2509241
• DOI: http://doi.org/10.4285/ATW2020.PO-1238

Abstract

Background
BK virus-associated nephropathy (BKVAN) is a known risk factor for allograft dysfunction and graft failure in kidney transplant recipients. The mainstay of treatment for BKVAN is reduction of immunosuppression and this may increase risk for acute rejection. We proposed to observe the effects of acute rejection on patients with BKVAN.
Methods
Using data from the Korean Organ Transplantation Registry, a nationwide organ transplantation database, we compared graft function, and allograft survival in BKVAN patients with or without biopsy proven acute rejection (BPAR).
Results
Among the 5,403 patients who received kidney transplantation between 2014 and June 2019, a total of 97 patients were diagnosed with BKVAN. Twenty-six patients (27%) developed BPAR within 6 months of BKVAN diagnosis, 71 patients did not. There were no differences in baseline characteristics, immunosuppression or BKVAN treatment methods between the BPAR and no BPAR groups. There was a significant decrease in allograft function in the BPAR group compared to the no BPAR group in both the 1-year (BPAR creatinine [Cr], 2.5±1.9 mg/dL vs. no BPAR Cr, 1.9±0.9 mg/dL; P=0.044) and 2-year follow-up period (BPAR Cr, 3.8±3.6 mg/dL vs. no BPAR Cr, 2.2±1.0 mg/dL; P=0.015). The BPAR group had lower allograft survival rates compared to the no BPAR group, although not statistically significant (P=0.474). On multivariate Cox regression analysis, MMF discontinuation was observed as a significant risk factor for rejection in BKVAN patients (hazard ratio, 4.000; 95% confidence interval [CI], 1.014– 15.775; P=0.048).
Conclusions
Acute rejection with BKVAN is associated with poorer allograft function and survival. Also, discontinuation of MMF as treatment for BKVAN increases risk for acute rejection.